To-be Listed
Industry Offer Price Lot Size Entry Fee Closing Date
Grey Market Date
Listing Date
Cutia Therapeutics
Biotechnology 20.65-24.75 200 5,000 2023-06-05 Data is not available 2023/06/12
CSPC PHARMA (01093.HK) delivered sluggish sales of anti-tumor products in 1Q, down 33.1% YoY to RMB1.4 billion, Nomura said in its report. The company's management considered that the sales were dented by epidemic and price reduction.On risk of National Centralized Medicines Procurement on NBP, CSPC PHARMA's top-selling ...
CCBI downed the target price of CSPC PHARMA (01093.HK) from $10.5 to $9.9, and maintained its Outperform rating in a research report.CCBI highlighted that the first quarter results of CSPC PHARMA were slightly weaker than market expectations, mainly due to the impact of Covid restrictions in the first two months of the year, wit...
Hong Kong equities closed down following a tumultuous session. The HSI opened higher and once stretched its uptick to as much as 132 pts. The index, however, receded due to the lack of support and closed at 18,551, down 195 pts or 1%; the HSCEI slid 82 pts or 1.3% to close at 6,251; the HSTECH waned 43 pts or 1.2% to close at 3,...
Hong Kong stocks were generally weak in the morning. HSI opened 80 points higher, once rising 132 points to a high of 18,879, but it reversed to fall 108 points and reached a low at 18,638. It closed the half-day at 18,697, down 49 points or 0.3%. HSCEI fell 37 points or 0.6% to 6,296. HSTECH dropped 15 points or 0.4% to 3,675. ...
On market resumption after long weekend, the HSI opened up by 80 pts or 0.4% to 18,827 today. Peaking at 18,879 without sustainability, it fell off to bottom at 18,638. It last printed at 18,689, down 57 pts or 0.3%, on total turnover of $53 billion. Blue chips displayed divergence. NTES-S (09999.HK) shot up 7.8% to $140.7, bein...
CSPC PHARMA (01093.HK) announced the financial results for the first quarter ended 31 March 2023. The revenue of the period hiked 2.3% YoY to RMB8.053 billion. The net profit amounted to RMB1.429 billion, elevating by 1.7% YoY. EPS was RMB11.99 fen.~AAStocks Financial NewsWeb Site:
Macquarie stated that large-scale Chinese pharmaceutical stocks should be able to defend from the mounting geopolitical risks, and listed its preferences for the sector in pecking order as follows: CSPC PHARMA (01093.HK), HANSOH PHARMA (03692.HK) and SINO BIOPHARM (01177.HK). The three above-mentioned pharmaceutical firms posses...
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.
You expressly agree that the use of this app/website is at your sole risk. Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party. Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account. Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance. Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor. Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance. Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.